Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph H Butterfield

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Immunology and Allergy Clinics of North America|August 26, 2006
Systemic mastocytosis: clinical manifestations and differential diagnosisJoseph H Butterfield
International Archives of Allergy and Immunology|November 14, 2019
Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell ActivationJoseph H Butterfield
Leukemia Research|January 16, 2009
Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndromeJoseph H Butterfield
Immunology and Allergy Clinics of North America|September 18, 2007
Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferonJoseph H Butterfield
Prostaglandins & Other Lipid Mediators|May 12, 2009
Survey of aspirin administration in systemic mastocytosisJoseph H Butterfield
Prostaglandins & Other Lipid Mediators|April 13, 2010
Increased leukotriene E4 excretion in systemic mastocytosisJoseph H Butterfield
Journal of Investigative Medicine High Impact Case Reports|January 18, 2021
Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and PrednisoneJoseph H Butterfield
The Journal of Allergy and Clinical Immunology. in Practice|March 2, 2023
Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation SyndromeJoseph H Butterfield
The Journal of Allergy and Clinical Immunology. Global|December 13, 2023
Metformin: A potential adjunct for treatment of systemic mastocytosisJoseph H Butterfield, Kathleen Bartemes
The Journal of Allergy and Clinical Immunology. Global|February 5, 2025
Acute/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndromeJoseph H Butterfield, Adela Taylor
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Immunology and Allergy Clinics of North America|August 26, 2006
Systemic mastocytosis: clinical manifestations and differential diagnosisJoseph H Butterfield
International Archives of Allergy and Immunology|November 14, 2019
Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell ActivationJoseph H Butterfield
Leukemia Research|January 16, 2009
Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndromeJoseph H Butterfield
Immunology and Allergy Clinics of North America|September 18, 2007
Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferonJoseph H Butterfield
Prostaglandins & Other Lipid Mediators|May 12, 2009
Survey of aspirin administration in systemic mastocytosisJoseph H Butterfield
Prostaglandins & Other Lipid Mediators|April 13, 2010
Increased leukotriene E4 excretion in systemic mastocytosisJoseph H Butterfield
Journal of Investigative Medicine High Impact Case Reports|January 18, 2021
Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and PrednisoneJoseph H Butterfield
The Journal of Allergy and Clinical Immunology. in Practice|March 2, 2023
Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation SyndromeJoseph H Butterfield
The Journal of Allergy and Clinical Immunology. Global|December 13, 2023
Metformin: A potential adjunct for treatment of systemic mastocytosisJoseph H Butterfield, Kathleen Bartemes
The Journal of Allergy and Clinical Immunology. Global|February 5, 2025
Acute/baseline ratios of all 3 MC mediator metabolites can enhance diagnosis and management of mast cell activation syndromeJoseph H Butterfield, Adela Taylor
Pageof 10